Impact BioMedical Inc. (IBO) 10-Year Financial Performance & Capital Metrics

IBO • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsSolid Tumor Oncology

AboutImpact BioMedical Inc. engages in the discovery and development of products and treatment options in specialty biopharmaceuticals and consumer healthcare. It provides Linebacker, a platform of small molecule electrophilically enhanced polyphenol compounds with application in oncology, inflammatory disorders, and neurology; and Laetose technology that is derived from a unique combination of sugar and inositol, which can inhibit the inflammatory and metabolic response of sugar alone. The company also develops functional fragrance formulation, a suite of functional fragrances containing specialized botanical ingredients with application as an antimicrobial, and as an additive in insect repellents, detergents, lotions, shampoo, fabrics, and other substances. In addition, it develops Equivir/Equivir G technology, a novel blend of polyphenols, which have demonstrated antiviral effects for use in as health supplements and medications. The company was incorporated in 2018 and is based in Houston, Texas.Show more

Revenue $2M
EBITDA $895K +130.8%
Net Income -$2M +52.7%
EPS (Diluted) -0.01
Gross Margin 100%
EBITDA Margin 38.4%
Operating Margin 23.67%
Net Margin -88.01%
ROE -11.56% +18.8%
ROIC 1.52% +120.9%
Debt/Equity 1.23 +187.1%
Interest Coverage 3.27 +136.0%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓High quality earnings: Operating CF exceeds net income

✗Weaknesses

✗Negative free cash flow
✗Weak momentum: RS Rating 17 (bottom 17%)
✗Shares diluted 21.5% in last year
✗Trading more than 30% below 52-week high
✗Expensive at 15.6x book value
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y259.91%

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-460.79%

EPS CAGR

10Y-

5Y-

3Y-

TTM-901.33%

ROCE

10Y Avg-252.07%

5Y Avg-311.75%

3Y Avg-5.96%

Latest2.63%

Peer Comparison

Solid Tumor Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
TLXTelix Pharmaceuticals Limited	2.53B	7.55	53.93	55.85%	3.98%	15.63%	0.36%	1.02
BBOTBridgeBio Oncology Therapeutics Inc.	1.01B	12.67	27.54			-25.73%
EXELExelixis, Inc.	11.81B	44.06	25.03	18.49%	29.63%	31.37%	5.37%	0.09
INBXInhibrx Biosciences, Inc.	1.1B	75.94	0.65	-88.89%	-110.78%	-421.09%		0.06
NUVBNuvation Bio Inc.	2.21B	6.46	-3.06		-8.13%	-66.74%		0.02
RLAYRelay Therapeutics, Inc.	1.35B	7.80	-3.31	-60.83%	-26.71%	-48.97%		0.06
ZLABZai Lab Limited	2.04B	18.39	-7.07	49.59%	-46.83%	-27.21%		0.18
URGNUroGen Pharma Ltd.	1B	21.45	-7.25	9.29%	-158.65%

Profit & Loss

	Mar 2018	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	50K	50K	0	2.33M
Revenue Growth %	-	-	-	-	-	0%	-1%	-
Cost of Goods Sold+	0	0	0	0	0	0	0	0
COGS % of Revenue	-	-	-	-	-	-	-	-
Gross Profit+	0	0	0	0	50K	50K	0	2.33M
Gross Margin %	-	-	-	-	1%	1%	-	1%
Gross Profit Growth %	-	-	-	-	-	0%	-1%	-
Operating Expenses+	176.23K	68.85K	680.02K	1.14M	3.45M	3.45M	4.03M	1.78M
OpEx % of Revenue	-	-	-	-	69.08%	69.08%	-	0.76%
Selling, General & Admin	176.23K	68.85K	237.72K	487.38K	1.05M	1.05M	1.1M	1.02M
SG&A % of Revenue	-	-	-	-	20.94%	20.94%	-	0.44%
Research & Development	0	0	442.3K	653.63K	1.23M	1.23M	1.69M	91.77K
R&D % of Revenue	-	-	-	-	24.52%	24.52%	-	0.04%
Other Operating Expenses	0	0	0	0	1.18M	1.18M	1.24M	670.05K
Operating Income+	63.95K	-33.86K	-680.02K	-1.14M	-3.4M	-3.4M	-4.03M	551.66K
Operating Margin %	-	-	-	-	-68.08%	-68.08%	-	0.24%
Operating Income Growth %	-	-1.53%	-19.08%	-0.68%	-1.98%	0%	-0.18%	1.14%
EBITDA+	225.09K	138K	0	0	-2.29M	-2.29M	-2.91M	895.13K
EBITDA Margin %	-	-	-	-	-45.82%	-45.82%	-	0.38%
EBITDA Growth %	-	-0.39%	-1%	-	-	0%	-0.27%	1.31%
D&A (Non-Cash Add-back)	161.14K	171.86K	680.02K	1.14M	1.11M	1.11M	1.12M	343.46K
EBIT	0	0	-680.02K	-1.14M	-7.41M	-7.41M	-3.96M	-1.88M
Net Interest Income+	8.12K	5.73K	562	0	-438K	-438K	-431K	-163.26K
Interest Income	8.12K	5.73K	562	0	24K	24K	13K	5.69K
Interest Expense	0	0	0	0	462K	462K	444K	168.95K
Other Income/Expense	-240.18K	-34.99K	-169.21K	0	-4.47M	-4.47M	-379K	-2.6M
Pretax Income+	-408.29K	-98.11K	-849.24K	-1.14M	-7.88M	-7.88M	-4.41M	-2.05M
Pretax Margin %	-	-	-	-	-157.52%	-157.52%	-	-0.88%
Income Tax+	0	0	0	-104.34K	-621K	-621K	0	0
Effective Tax Rate %	1%	1%	0.69%	0.67%	0.9%	0.9%	0.98%	1%
Net Income+	-408.29K	-98.11K	-590.08K	-760.07K	-7.05M	-7.05M	-4.34M	-2.05M
Net Margin %	-	-	-	-	-141.02%	-141.02%	-	-0.88%
Net Income Growth %	-	0.76%	-5.01%	-0.29%	-8.28%	0%	0.39%	0.53%
Net Income (Continuing)	-408.29K	-98.11K	-849.24K	-1.04M	-7.25M	-7.25M	-4.41M	-2.05M
Discontinued Operations	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	3.31M	3.11M	3.04M	2.98M
EPS (Diluted)+	-0.04	-0.01	-0.01	-0.01	-0.61	-0.61	-0.01	-0.01
EPS Growth %	-	0.75%	0%	-0.08%	-55.48%	0%	0.98%	0%
EPS (Basic)	-0.04	-0.01	-0.01	-0.01	-0.61	-0.61	-0.01	-0.01
Diluted Shares Outstanding	10.21M	9.81M	11.83M	70.5K	60.25M	11.5M	191.3M	232.5M
Basic Shares Outstanding	10.21M	9.81M	11.83M	70.5K	11.5M	11.5M	191.3M	232.5M
Dividend Payout Ratio	-	-	-	-	-	-	-	-

Balance Sheet

	Mar 2018	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	320.66K	217.21K	115.34K	71.7K	287K	122K	332K	2.45M
Cash & Short-Term Investments	51.92K	204.93K	97.67K	52.14K	46K	2K	1K	2M
Cash Only	51.92K	204.93K	97.67K	52.14K	46K	2K	1K	2M
Short-Term Investments	0	0	0	0	0	0	0	0
Accounts Receivable	28.62K	4.38K	35.19K	14.06K	197K	16K	331K	184K
Days Sales Outstanding	-	-	-	-	1.44K	116.8	-	28.81
Inventory	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-
Other Current Assets	0	0	-17.52K	0	1K	43K	0	0
Total Non-Current Assets+	0	0	1.27K	1.04K	56.14M	46.38M	44.3M	17.84M
Property, Plant & Equipment	0	0	1.27K	1.04K	0	276K	287K	17K
Fixed Asset Turnover	-	-	-	-	-	0.18x	-	137.12x
Goodwill	0	0	0	0	25.09M	25.09M	25.09M	0
Intangible Assets	0	0	0	0	21.15M	20.03M	18.92M	17.81M
Long-Term Investments	0	0	0	0	4.82M	782K	0	17K
Other Non-Current Assets	0	0	0	0	5.08M	190K	0	0
Total Assets+	320.66K	217.21K	116.61K	72.74K	56.42M	46.5M	44.63M	20.29M
Asset Turnover	-	-	-	-	0.00x	0.00x	-	0.11x
Asset Growth %	-	-0.32%	-0.46%	-0.38%	774.67%	-0.18%	-0.04%	-0.55%
Total Current Liabilities+	25.44K	20.09K	21.72K	18.03K	12.64M	10.59M	13.14M	9.79M
Accounts Payable	0	0	0	0	115K	539K	832K	713K
Days Payables Outstanding	-	-	-	-	-	-	-	-
Short-Term Debt	0	0	0	0	12.52M	9.99M	12.07M	8.88M
Deferred Revenue (Current)	0	0	0	0	0	0	0	0
Other Current Liabilities	0	0	21.72K	18.03K	0	0	0	0
Current Ratio	12.61x	10.81x	5.31x	3.98x	0.02x	0.01x	0.03x	0.25x
Quick Ratio	12.61x	10.81x	5.31x	3.98x	0.02x	0.01x	0.03x	0.25x
Cash Conversion Cycle	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	0	0	0	60K	3.86M	3.23M	3.23M	3.27M
Long-Term Debt	0	0	0	60K	0	0	0	0
Capital Lease Obligations	0	0	0	0	0	0	0	0
Deferred Tax Liabilities	0	0	0	0	3.86M	3.23M	3.23M	3.27M
Other Non-Current Liabilities	0	0	0	0	0	0	0	0
Total Liabilities	25.44K	20.09K	21.72K	78.03K	16.5M	13.83M	16.37M	13.05M
Total Debt+	0	0	0	60K	12.52M	9.99M	12.07M	8.88M
Net Debt	-51.92K	-204.93K	-97.67K	7.86K	12.48M	9.99M	12.07M	6.88M
Debt / Equity	-	-	-	-	0.31x	0.31x	0.43x	1.23x
Debt / EBITDA	-	-	-	-	-	-	-	9.92x
Net Debt / EBITDA	-0.23x	-1.49x	-	-	-	-	-	7.68x
Interest Coverage	-	-	-	-	-7.37x	-7.37x	-9.07x	3.27x
Total Equity+	295.22K	197.12K	94.89K	-5.28K	39.92M	32.67M	28.26M	7.24M
Equity Growth %	-	-0.33%	-0.52%	-1.06%	7558.07%	-0.18%	-0.13%	-0.74%
Book Value per Share	0.03	0.02	0.01	-0.07	0.66	2.84	0.15	0.03
Total Shareholders' Equity	295.22K	197.12K	94.89K	-5.28K	36.61M	29.56M	25.22M	4.26M
Common Stock	595.51K	595.51K	619.1K	696.75K	125K	70K	10K	11K
Retained Earnings	-408.29K	-506.4K	-624.71K	-831.93K	-1.57M	-8.63M	-12.96M	-37.67M
Treasury Stock	-	-	0	-	0	0	0	0
Accumulated OCI	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	3.31M	3.11M	3.04M	2.98M

Cash Flow

	Mar 2018	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-320.34K	-71.99K	-121.98K	-1.14K	-3.25M	-4.33M	-2.85M	-3.92M
Operating CF Margin %	-	-	-	-	-64.99%	-86.66%	-	-1.68%
Operating CF Growth %	-	0.78%	-0.69%	0.99%	-2842.16%	-0.33%	0.34%	-0.37%
Net Income	-408.29K	-98.11K	-118.31K	-760	-3.87M	-10.5M	-4.41M	-24.77M
Depreciation & Amortization	0	0	255	0	69.86K	266.4K	1.12M	1.12M
Stock-Based Compensation	94K	0	0	0	0	903.54K	0	19K
Deferred Taxes	0	0	0	0	0	2.71M	0	33K
Other Non-Cash Items	0	0	0	-377	829.56K	2.79M	0	20.29M
Working Capital Changes	-6.05K	26.12K	-3.93K	-5	-281.93K	-507.7K	436K	-608K
Change in Receivables	-27.77K	24.24K	-5.81K	0	0	0	-128K	128K
Change in Inventory	0	0	0	0	0	0	0	0
Change in Payables	0	0	0	0	279.91K	-474.4K	293K	-436K
Cash from Investing+	-225K	225K	-26.53K	-804	-42.93K	-2.09M	-15K	2K
Capital Expenditures	0	0	-1.53K	0	0	-95.68K	-18K	0
CapEx % of Revenue	-	-	-	-	5.52%	1.91%	-	-
Acquisitions	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-
Other Investing	-225K	225K	-25K	-804	-42.93K	54.78K	3K	2K
Cash from Financing+	209.51K	0	16.09K	1.9K	3.38M	7.01M	2.87M	5.92M
Debt Issued (Net)	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	-410K	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-
Other Financing	0	0	16.09K	1.9K	1.25M	4.46M	0	0
Net Change in Cash	-	-	-	-	-	-	-	-
Free Cash Flow+	-320.34K	-71.99K	-123.51K	-1.14K	-3.25M	-4.43M	-2.87M	-3.92M
FCF Margin %	-	-	-	-	-64.99%	-88.58%	-	-1.68%
FCF Growth %	-	0.78%	-0.72%	0.99%	-2842.16%	-0.36%	0.35%	-0.37%
FCF per Share	-0.03	-0.01	-0.01	-0.02	-0.05	-0.39	-0.01	-0.02
FCF Conversion (FCF/Net Income)	0.78x	0.73x	0.21x	0.00x	0.46x	0.61x	0.66x	1.91x
Interest Paid	-	-	0	0	0	0	0	0
Taxes Paid	-	-	0	0	0	0	0	0

Key Ratios

Metric	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-138.3%	-39.85%	-404.16%	-1696.43%	-35.33%	-19.43%	-14.23%	-11.56%
Return on Invested Capital (ROIC)	-	-21.57%	-	-33156.13%	-9.74%	-5.37%	-7.28%	1.52%
Gross Margin	-	-	-	-	100%	100%	-	100%
Net Margin	-	-	-	-	-14102%	-14102%	-	-88.01%
Debt / Equity	-	-	-	-	0.31x	0.31x	0.43x	1.23x
Interest Coverage	-	-	-	-	-7.37x	-7.37x	-9.07x	3.27x
FCF Conversion	0.78x	0.73x	0.21x	0.00x	0.46x	0.61x	0.66x	1.91x
Revenue Growth	-	-	-	-	-	0%	-100%	-

Frequently Asked Questions

Growth & Financials

Impact BioMedical Inc. (IBO) reported $2.3M in revenue for fiscal year 2024.

Impact BioMedical Inc. (IBO) grew revenue by 0.0% over the past year. Growth has been modest.

Impact BioMedical Inc. (IBO) reported a net loss of $25.0M for fiscal year 2024.

Dividend & Returns

Impact BioMedical Inc. (IBO) has a return on equity (ROE) of -11.6%. Negative ROE indicates the company is unprofitable.

Impact BioMedical Inc. (IBO) had negative free cash flow of $3.4M in fiscal year 2024, likely due to heavy capital investments.

← Back to Screener

US Stock Screener

...

Impact BioMedical Inc. (IBO) 10-Year Financial Performance & Capital Metrics

IBO • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsSolid Tumor Oncology

Revenue $2M
EBITDA $895K +130.8%
Net Income -$2M +52.7%
EPS (Diluted) -0.01
Gross Margin 100%
EBITDA Margin 38.4%
Operating Margin 23.67%
Net Margin -88.01%
ROE -11.56% +18.8%
ROIC 1.52% +120.9%
Debt/Equity 1.23 +187.1%
Interest Coverage 3.27 +136.0%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓High quality earnings: Operating CF exceeds net income

✗Weaknesses

✗Negative free cash flow
✗Weak momentum: RS Rating 17 (bottom 17%)
✗Shares diluted 21.5% in last year
✗Trading more than 30% below 52-week high
✗Expensive at 15.6x book value
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y259.91%

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-460.79%

EPS CAGR

10Y-

5Y-

3Y-

TTM-901.33%

ROCE

10Y Avg-252.07%

5Y Avg-311.75%

3Y Avg-5.96%

Latest2.63%

Peer Comparison

Solid Tumor Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
TLXTelix Pharmaceuticals Limited	2.53B	7.55	53.93	55.85%	3.98%	15.63%	0.36%	1.02
BBOTBridgeBio Oncology Therapeutics Inc.	1.01B	12.67	27.54			-25.73%
EXELExelixis, Inc.	11.81B	44.06	25.03	18.49%	29.63%	31.37%	5.37%	0.09
INBXInhibrx Biosciences, Inc.	1.1B	75.94	0.65	-88.89%	-110.78%	-421.09%		0.06
NUVBNuvation Bio Inc.	2.21B	6.46	-3.06		-8.13%	-66.74%		0.02
RLAYRelay Therapeutics, Inc.	1.35B	7.80	-3.31	-60.83%	-26.71%	-48.97%		0.06
ZLABZai Lab Limited	2.04B	18.39	-7.07	49.59%	-46.83%	-27.21%		0.18
URGNUroGen Pharma Ltd.	1B	21.45	-7.25	9.29%	-158.65%

Profit & Loss

	Mar 2018	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	50K	50K	0	2.33M
Revenue Growth %	-	-	-	-	-	0%	-1%	-
Cost of Goods Sold+	0	0	0	0	0	0	0	0
COGS % of Revenue	-	-	-	-	-	-	-	-
Gross Profit+	0	0	0	0	50K	50K	0	2.33M
Gross Margin %	-	-	-	-	1%	1%	-	1%
Gross Profit Growth %	-	-	-	-	-	0%	-1%	-
Operating Expenses+	176.23K	68.85K	680.02K	1.14M	3.45M	3.45M	4.03M	1.78M
OpEx % of Revenue	-	-	-	-	69.08%	69.08%	-	0.76%
Selling, General & Admin	176.23K	68.85K	237.72K	487.38K	1.05M	1.05M	1.1M	1.02M
SG&A % of Revenue	-	-	-	-	20.94%	20.94%	-	0.44%
Research & Development	0	0	442.3K	653.63K	1.23M	1.23M	1.69M	91.77K
R&D % of Revenue	-	-	-	-	24.52%	24.52%	-	0.04%
Other Operating Expenses	0	0	0	0	1.18M	1.18M	1.24M	670.05K
Operating Income+	63.95K	-33.86K	-680.02K	-1.14M	-3.4M	-3.4M	-4.03M	551.66K
Operating Margin %	-	-	-	-	-68.08%	-68.08%	-	0.24%
Operating Income Growth %	-	-1.53%	-19.08%	-0.68%	-1.98%	0%	-0.18%	1.14%
EBITDA+	225.09K	138K	0	0	-2.29M	-2.29M	-2.91M	895.13K
EBITDA Margin %	-	-	-	-	-45.82%	-45.82%	-	0.38%
EBITDA Growth %	-	-0.39%	-1%	-	-	0%	-0.27%	1.31%
D&A (Non-Cash Add-back)	161.14K	171.86K	680.02K	1.14M	1.11M	1.11M	1.12M	343.46K
EBIT	0	0	-680.02K	-1.14M	-7.41M	-7.41M	-3.96M	-1.88M
Net Interest Income+	8.12K	5.73K	562	0	-438K	-438K	-431K	-163.26K
Interest Income	8.12K	5.73K	562	0	24K	24K	13K	5.69K
Interest Expense	0	0	0	0	462K	462K	444K	168.95K
Other Income/Expense	-240.18K	-34.99K	-169.21K	0	-4.47M	-4.47M	-379K	-2.6M
Pretax Income+	-408.29K	-98.11K	-849.24K	-1.14M	-7.88M	-7.88M	-4.41M	-2.05M
Pretax Margin %	-	-	-	-	-157.52%	-157.52%	-	-0.88%
Income Tax+	0	0	0	-104.34K	-621K	-621K	0	0
Effective Tax Rate %	1%	1%	0.69%	0.67%	0.9%	0.9%	0.98%	1%
Net Income+	-408.29K	-98.11K	-590.08K	-760.07K	-7.05M	-7.05M	-4.34M	-2.05M
Net Margin %	-	-	-	-	-141.02%	-141.02%	-	-0.88%
Net Income Growth %	-	0.76%	-5.01%	-0.29%	-8.28%	0%	0.39%	0.53%
Net Income (Continuing)	-408.29K	-98.11K	-849.24K	-1.04M	-7.25M	-7.25M	-4.41M	-2.05M
Discontinued Operations	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	3.31M	3.11M	3.04M	2.98M
EPS (Diluted)+	-0.04	-0.01	-0.01	-0.01	-0.61	-0.61	-0.01	-0.01
EPS Growth %	-	0.75%	0%	-0.08%	-55.48%	0%	0.98%	0%
EPS (Basic)	-0.04	-0.01	-0.01	-0.01	-0.61	-0.61	-0.01	-0.01
Diluted Shares Outstanding	10.21M	9.81M	11.83M	70.5K	60.25M	11.5M	191.3M	232.5M
Basic Shares Outstanding	10.21M	9.81M	11.83M	70.5K	11.5M	11.5M	191.3M	232.5M
Dividend Payout Ratio	-	-	-	-	-	-	-	-

Balance Sheet

	Mar 2018	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	320.66K	217.21K	115.34K	71.7K	287K	122K	332K	2.45M
Cash & Short-Term Investments	51.92K	204.93K	97.67K	52.14K	46K	2K	1K	2M
Cash Only	51.92K	204.93K	97.67K	52.14K	46K	2K	1K	2M
Short-Term Investments	0	0	0	0	0	0	0	0
Accounts Receivable	28.62K	4.38K	35.19K	14.06K	197K	16K	331K	184K
Days Sales Outstanding	-	-	-	-	1.44K	116.8	-	28.81
Inventory	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-
Other Current Assets	0	0	-17.52K	0	1K	43K	0	0
Total Non-Current Assets+	0	0	1.27K	1.04K	56.14M	46.38M	44.3M	17.84M
Property, Plant & Equipment	0	0	1.27K	1.04K	0	276K	287K	17K
Fixed Asset Turnover	-	-	-	-	-	0.18x	-	137.12x
Goodwill	0	0	0	0	25.09M	25.09M	25.09M	0
Intangible Assets	0	0	0	0	21.15M	20.03M	18.92M	17.81M
Long-Term Investments	0	0	0	0	4.82M	782K	0	17K
Other Non-Current Assets	0	0	0	0	5.08M	190K	0	0
Total Assets+	320.66K	217.21K	116.61K	72.74K	56.42M	46.5M	44.63M	20.29M
Asset Turnover	-	-	-	-	0.00x	0.00x	-	0.11x
Asset Growth %	-	-0.32%	-0.46%	-0.38%	774.67%	-0.18%	-0.04%	-0.55%
Total Current Liabilities+	25.44K	20.09K	21.72K	18.03K	12.64M	10.59M	13.14M	9.79M
Accounts Payable	0	0	0	0	115K	539K	832K	713K
Days Payables Outstanding	-	-	-	-	-	-	-	-
Short-Term Debt	0	0	0	0	12.52M	9.99M	12.07M	8.88M
Deferred Revenue (Current)	0	0	0	0	0	0	0	0
Other Current Liabilities	0	0	21.72K	18.03K	0	0	0	0
Current Ratio	12.61x	10.81x	5.31x	3.98x	0.02x	0.01x	0.03x	0.25x
Quick Ratio	12.61x	10.81x	5.31x	3.98x	0.02x	0.01x	0.03x	0.25x
Cash Conversion Cycle	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	0	0	0	60K	3.86M	3.23M	3.23M	3.27M
Long-Term Debt	0	0	0	60K	0	0	0	0
Capital Lease Obligations	0	0	0	0	0	0	0	0
Deferred Tax Liabilities	0	0	0	0	3.86M	3.23M	3.23M	3.27M
Other Non-Current Liabilities	0	0	0	0	0	0	0	0
Total Liabilities	25.44K	20.09K	21.72K	78.03K	16.5M	13.83M	16.37M	13.05M
Total Debt+	0	0	0	60K	12.52M	9.99M	12.07M	8.88M
Net Debt	-51.92K	-204.93K	-97.67K	7.86K	12.48M	9.99M	12.07M	6.88M
Debt / Equity	-	-	-	-	0.31x	0.31x	0.43x	1.23x
Debt / EBITDA	-	-	-	-	-	-	-	9.92x
Net Debt / EBITDA	-0.23x	-1.49x	-	-	-	-	-	7.68x
Interest Coverage	-	-	-	-	-7.37x	-7.37x	-9.07x	3.27x
Total Equity+	295.22K	197.12K	94.89K	-5.28K	39.92M	32.67M	28.26M	7.24M
Equity Growth %	-	-0.33%	-0.52%	-1.06%	7558.07%	-0.18%	-0.13%	-0.74%
Book Value per Share	0.03	0.02	0.01	-0.07	0.66	2.84	0.15	0.03
Total Shareholders' Equity	295.22K	197.12K	94.89K	-5.28K	36.61M	29.56M	25.22M	4.26M
Common Stock	595.51K	595.51K	619.1K	696.75K	125K	70K	10K	11K
Retained Earnings	-408.29K	-506.4K	-624.71K	-831.93K	-1.57M	-8.63M	-12.96M	-37.67M
Treasury Stock	-	-	0	-	0	0	0	0
Accumulated OCI	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	3.31M	3.11M	3.04M	2.98M

Cash Flow

	Mar 2018	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-320.34K	-71.99K	-121.98K	-1.14K	-3.25M	-4.33M	-2.85M	-3.92M
Operating CF Margin %	-	-	-	-	-64.99%	-86.66%	-	-1.68%
Operating CF Growth %	-	0.78%	-0.69%	0.99%	-2842.16%	-0.33%	0.34%	-0.37%
Net Income	-408.29K	-98.11K	-118.31K	-760	-3.87M	-10.5M	-4.41M	-24.77M
Depreciation & Amortization	0	0	255	0	69.86K	266.4K	1.12M	1.12M
Stock-Based Compensation	94K	0	0	0	0	903.54K	0	19K
Deferred Taxes	0	0	0	0	0	2.71M	0	33K
Other Non-Cash Items	0	0	0	-377	829.56K	2.79M	0	20.29M
Working Capital Changes	-6.05K	26.12K	-3.93K	-5	-281.93K	-507.7K	436K	-608K
Change in Receivables	-27.77K	24.24K	-5.81K	0	0	0	-128K	128K
Change in Inventory	0	0	0	0	0	0	0	0
Change in Payables	0	0	0	0	279.91K	-474.4K	293K	-436K
Cash from Investing+	-225K	225K	-26.53K	-804	-42.93K	-2.09M	-15K	2K
Capital Expenditures	0	0	-1.53K	0	0	-95.68K	-18K	0
CapEx % of Revenue	-	-	-	-	5.52%	1.91%	-	-
Acquisitions	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-
Other Investing	-225K	225K	-25K	-804	-42.93K	54.78K	3K	2K
Cash from Financing+	209.51K	0	16.09K	1.9K	3.38M	7.01M	2.87M	5.92M
Debt Issued (Net)	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	-410K	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-
Other Financing	0	0	16.09K	1.9K	1.25M	4.46M	0	0
Net Change in Cash	-	-	-	-	-	-	-	-
Free Cash Flow+	-320.34K	-71.99K	-123.51K	-1.14K	-3.25M	-4.43M	-2.87M	-3.92M
FCF Margin %	-	-	-	-	-64.99%	-88.58%	-	-1.68%
FCF Growth %	-	0.78%	-0.72%	0.99%	-2842.16%	-0.36%	0.35%	-0.37%
FCF per Share	-0.03	-0.01	-0.01	-0.02	-0.05	-0.39	-0.01	-0.02
FCF Conversion (FCF/Net Income)	0.78x	0.73x	0.21x	0.00x	0.46x	0.61x	0.66x	1.91x
Interest Paid	-	-	0	0	0	0	0	0
Taxes Paid	-	-	0	0	0	0	0	0

Key Ratios

Metric	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-138.3%	-39.85%	-404.16%	-1696.43%	-35.33%	-19.43%	-14.23%	-11.56%
Return on Invested Capital (ROIC)	-	-21.57%	-	-33156.13%	-9.74%	-5.37%	-7.28%	1.52%
Gross Margin	-	-	-	-	100%	100%	-	100%
Net Margin	-	-	-	-	-14102%	-14102%	-	-88.01%
Debt / Equity	-	-	-	-	0.31x	0.31x	0.43x	1.23x
Interest Coverage	-	-	-	-	-7.37x	-7.37x	-9.07x	3.27x
FCF Conversion	0.78x	0.73x	0.21x	0.00x	0.46x	0.61x	0.66x	1.91x
Revenue Growth	-	-	-	-	-	0%	-100%	-

Frequently Asked Questions

Growth & Financials

Impact BioMedical Inc. (IBO) reported $2.3M in revenue for fiscal year 2024.

Impact BioMedical Inc. (IBO) grew revenue by 0.0% over the past year. Growth has been modest.

Impact BioMedical Inc. (IBO) reported a net loss of $25.0M for fiscal year 2024.

Dividend & Returns

Impact BioMedical Inc. (IBO) has a return on equity (ROE) of -11.6%. Negative ROE indicates the company is unprofitable.

Impact BioMedical Inc. (IBO) had negative free cash flow of $3.4M in fiscal year 2024, likely due to heavy capital investments.